Summary
In vivo19F resonance spectroscopy measurements of trifluorinated neuroleptics (fluphenazine and trifluoperazine) and later trifluorinated antide-pressants (fluoxetine and fluvoxamine) began with animal experiments in 1983. Using rats which have been treated with high oral doses of fluphenazine over a period of three weeks in the beginning of these experiments the measurement time was very long (up to 10 h). The application of better techniques using surface coils led to marked improvement of the signal noise ratio and measurement times in animal experiments could be reduced to minutes. These results encouraged us and other groups to perform experiments in humans to detect and try to estimate brain levels of trifluorinated neuroleptics and antide-pressants. The present data of several research groups demonstrate that19F MR spectroscopy has the potential of becoming a valuable tool for monitoring drug levels at the site of action. The extension of the animal studies to humans might facilitate a better treatment of schizophrenic and depressive patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Albert K, Bartels M, Kruppa G, Mann K, Schroth G, Tabarelli S, Zabel M (1984) Untersuchung fluorsubstituierter Psychopharmaka mittels NMR. In: Pfannenstiel P, Meves M (Hrsg) Die NMR Tomographie. Klinischer Einsatz und Wirtschaftlichkeit. G Thieme, Stuttgart S 34–36
Albert K, Rembold H, Kruppa G, Bayer E, Bartels M, Schmalzing G (1990) In vivo19F nuclear magnetic resonance spectroscopy of trifluorinated neuroleptics in the rat. NMR Biomed 3: 120–123
Bartels M, Albert K, Kruppa G, Mann K, Schroth G, Tabarelli S, Zabel M (1986) Fluorinated psychopharmacological agents: noninvasive observation by fluorine-19 nuclear magnetic resonance. Psychiatry Res 18: 197–201
Bartels M, Günther U, Albert K, Mann K, Schuff N, Stuckstedte H (1991)19F Nuclear magnetic resonance spectroscopy of neuroleptics: the first in vivo pharmacokinetics of trifluoperazine in the rat brain and the first in vivo spectrum of fluphenazine in the human brain. Biol Psychiatry 30: 656–662
Buchsbaum MS (1987) Positron emission tomography in schizophrenia. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, p 783
Durst P, Schuff N, Crocq MA, Mokrani MC, Macher JP (1990) Noninvasive in vivo detection of a fluorinated neuroleptic in the human brain by19F nuclear magnetic resonance spectroscopy. Psychiatry Res Neuroimaging 35: 107–114
Günther U, Albert K (1993) In vivo19F nuclear magnetic resonance of a monofluorinated neuroleptic in the rat. NMR Biomed 6: 27–31
Joergensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. In: Bridge JW, Chasseaud LF (eds) Progress in drug metabolism, vol 9. Taylor and Francis, London Philadelphia, p 111–174
Karson CN, Newton JEO, Livingston R, Jolly JB, Cooper TB, Sprigg J, Komoroski RA (1993) Human brain fluoxetine concentrations. J Neuropsych Clin Neurosci 5: 322–329
Komoroski RA, Newton JEO, Karson CN, Cardwell D, Sprigg J (1991) Detection of psychoactive drugs in vivo in humans using19F NMR spectroscopy. Biol Psychiatry 29: 711–714
Komoroski RA, Newton JEO, Cardwell D, Sprigg J, Pearce J, Karson CN (1994) In vivo19F spin relaxation and localized spectroscopy of fluoxetine in human brain. Magn Reson Med 31: 204–211
Korpi ER, Kleinmann JE, Costakos DT, Linnoila M, Wyatt RJ (1984) Reduced haloperidol in the post-mortem brains of haloperidol-treated patients. Psychiatry Res 11: 259–269
Sunderland T, Cohen BM (1986) Blood to brain distribution of neuroleptics. Psychiatry Res 20: 299–305
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bartels, M., Albert, K. Detection of psychoactive drugs using19F MR spectroscopy. J. Neural Transmission 99, 1–6 (1995). https://doi.org/10.1007/BF01271467
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01271467